SK181099A3 - Solubilized sertraline compositions - Google Patents

Solubilized sertraline compositions Download PDF

Info

Publication number
SK181099A3
SK181099A3 SK1810-99A SK181099A SK181099A3 SK 181099 A3 SK181099 A3 SK 181099A3 SK 181099 A SK181099 A SK 181099A SK 181099 A3 SK181099 A3 SK 181099A3
Authority
SK
Slovakia
Prior art keywords
composition
sertraline
solubilizing agent
acid
concentration
Prior art date
Application number
SK1810-99A
Other languages
English (en)
Slovak (sk)
Inventor
Dwayne Thomas Friesen
Scott Max Herbig
Ravi Mysore Shanker
James Blair West
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK181099(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SK181099A3 publication Critical patent/SK181099A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1810-99A 1997-07-01 1998-06-15 Solubilized sertraline compositions SK181099A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01
PCT/IB1998/000933 WO1999001120A1 (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Publications (1)

Publication Number Publication Date
SK181099A3 true SK181099A3 (en) 2000-07-11

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1810-99A SK181099A3 (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Country Status (34)

Country Link
EP (1) EP0999829A1 (tr)
JP (1) JP2000514100A (tr)
KR (1) KR100366373B1 (tr)
CN (1) CN1261794A (tr)
AP (1) AP1192A (tr)
AR (3) AR015917A1 (tr)
AU (1) AU742535B2 (tr)
BG (1) BG103918A (tr)
BR (1) BR9810739A (tr)
CA (1) CA2290974C (tr)
CO (1) CO4940495A1 (tr)
DZ (1) DZ2548A1 (tr)
EA (1) EA002481B1 (tr)
HN (1) HN1998000102A (tr)
HR (1) HRP980377A2 (tr)
HU (1) HUP0002236A3 (tr)
ID (1) ID23429A (tr)
IL (1) IL133076A (tr)
IS (1) IS5260A (tr)
MA (1) MA24587A1 (tr)
NO (1) NO996520L (tr)
OA (1) OA11243A (tr)
PA (1) PA8454301A1 (tr)
PE (1) PE97199A1 (tr)
PL (1) PL337804A1 (tr)
SK (1) SK181099A3 (tr)
TN (1) TNSN98124A1 (tr)
TR (1) TR199903297T2 (tr)
TW (1) TW550087B (tr)
UA (1) UA67741C2 (tr)
UY (1) UY25071A1 (tr)
WO (1) WO1999001120A1 (tr)
YU (1) YU68299A (tr)
ZA (1) ZA985708B (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1738749A1 (en) 1999-12-23 2007-01-03 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
ES2439582T3 (es) * 2007-03-12 2014-01-23 Dsm Ip Assets B.V. Composiciones cosméticas
TW201129557A (en) * 2009-12-29 2011-09-01 Kowa Co Pharmaceutical composition for oral administration
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
EP0415612B1 (en) * 1989-08-30 1993-11-10 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
TR199903297T2 (tr) 2000-07-21
CN1261794A (zh) 2000-08-02
OA11243A (en) 2003-07-24
AP9801280A0 (en) 1998-06-30
TNSN98124A1 (fr) 2005-03-15
NO996520D0 (no) 1999-12-28
TW550087B (en) 2003-09-01
PL337804A1 (en) 2000-09-11
NO996520L (no) 2000-02-29
AR015917A1 (es) 2001-05-30
IL133076A (en) 2003-12-10
JP2000514100A (ja) 2000-10-24
UA67741C2 (uk) 2004-07-15
YU68299A (sh) 2002-06-19
UY25071A1 (es) 2000-12-29
AR040280A2 (es) 2005-03-23
IS5260A (is) 1999-11-19
EA199900962A1 (ru) 2000-08-28
HN1998000102A (es) 1999-01-08
CA2290974C (en) 2004-04-27
PA8454301A1 (es) 2000-09-29
AP1192A (en) 2003-07-23
MA24587A1 (fr) 1998-12-31
CO4940495A1 (es) 2000-07-24
WO1999001120A1 (en) 1999-01-14
AU742535B2 (en) 2002-01-03
AU7544898A (en) 1999-01-25
BR9810739A (pt) 2000-09-12
HRP980377A2 (en) 1999-04-30
KR100366373B1 (ko) 2003-01-14
HUP0002236A3 (en) 2003-12-29
IL133076A0 (en) 2001-03-19
PE97199A1 (es) 1999-10-05
AR040279A2 (es) 2005-03-23
DZ2548A1 (fr) 2003-02-08
BG103918A (en) 2000-07-31
KR20010013365A (ko) 2001-02-26
EP0999829A1 (en) 2000-05-17
ID23429A (id) 2000-04-20
CA2290974A1 (en) 1999-01-14
HUP0002236A2 (hu) 2003-08-28
EA002481B1 (ru) 2002-06-27
ZA985708B (en) 2000-01-10

Similar Documents

Publication Publication Date Title
US4803081A (en) New pharmaceutical preparations with extended release
EP0194838B1 (en) Controlled-release pharmaceutical formulation
US5525354A (en) Pharmaceutical preparation and process for its manufacture
RU2442574C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
JP2002080398A (ja) ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物
JPH10511112A (ja) ダリフェナシン含有製剤
ES2852899T3 (es) Formulaciones estabilizadas de molindona
DE69816624T2 (de) Verabreichungsform für sertralin mit verzögerter wirkstofffreigabe
JP2009519943A (ja) イラプラゾールの医薬組成物
SK181099A3 (en) Solubilized sertraline compositions
PL186790B1 (pl) Farmaceutyczna kompozycja doustna zawierająca 5-ASA i zastosowanie 5-ASA do jej wytwarzania
JPH0451528B2 (tr)
CZ464199A3 (cs) Solubilizované sertralinové kompozice
US20040208926A1 (en) Solubilized sertraline compositions
KR20010078703A (ko) 신규 제약 제제
BR112021012259A2 (pt) Composição farmacêutica contendo hidrocloreto de tansulosina com excelente resistência a ácidos e método de preparação da mesma
NZ501250A (en) Solubilized sertraline compositions
MXPA99012101A (en) Solubilized sertraline compositions
JP2005104914A (ja) 塩基性薬剤含有製剤
JP2001122779A (ja) 経口投与用シクロスポリン含有ミクロエマルジョン濃縮液
HRP920630A2 (en) New pharmaceutical preparations having extended delivery
CZ464399A3 (cs) Dávkovači formy sertralinu s řízeným uvolňováním